Biocardia Stock News

BioCardia BCDA +32%. Biophytis BPTS +17%. Kiromic BioPharma KRBP -17%. Mainz Biomed (MYNZ) -9%.

The FDA has granted Breakthrough Device Designation for BioCardia Inc's  BCDA CardiAMP Cell Therapy System to treat heart failure.  Get the Inside Access Traders Are Using to Profit More and Win

The U.S. Food and Drug Administration ((FDA)) granted breakthrough device designation to BioCardia''s (BCDA) CardiAMP Cell Therapy System to treat heart failure.The company said it…

BioCardia (BCDA) +32% receives FDA breakthrough device designation for CardiAMP cell therapy system for heart failure.Bon Natural Life BON +29% on FY results.Lightning

HC Wainwright assumed coverage on shares of BioCardia (NASDAQ:BCDA) in a report published on Monday morning, Analyst Price Targets reports. The firm issued a buy rating and a $9.00 target price on the stock. Separately, Zacks Investment Research upgraded BioCardia from a sell rating to a hold rating in a research report on Tuesday, August [] The post BioCardia (NASDAQ:BCDA) Coverage Initiated by Analysts at HC Wainwright appeared first on ETF Daily News .

In last trading session, BioCardia Inc. (NASDAQ:BCDA) saw 1.53 million shares changing hands with its beta currently measuring 1.42. Companys recent per share price level of $2.24 trading at $0.13 or 6.16% at ring of the bell on the day assigns it a market valuation of $36.87M. That closing price of BCDAs stock is at BioCardia Inc. (NASDAQ:BCDA) Has Recovered -41.51% To Date, But An Additional -144.64% Is Possible. Read More »

BioCardia Inc. (NASDAQ:BCDA) has a beta value of 1.42 and has seen 0.63 million shares traded in the recent trading session. The company, currently valued at $28.80M, closed the recent trade at $2.01 per share which meant it gained $0.26 on the day or 14.86% during that session. The BCDA stock price is -172.64% off BioCardia Inc. (BCDA) Suffers From Weak Fundamental Momentum Read More »

BioCardia (NASDAQ:BCDA) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent ratings for BioCardia and REGENXBIO, as provided by MarketBeat. []

Marshall Wace LLP cut its stake in shares of BioCardia, Inc. (NASDAQ:BCDA) by 45.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,680 shares of the companys stock after selling 18,282 shares during the period. Marshall Wace LLP owned 0.13% of []

Virtu Financial LLC acquired a new stake in shares of BioCardia, Inc. (NASDAQ:BCDA) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,264 shares of the companys stock, valued at approximately $132,000. Virtu Financial LLC owned about 0.20% of BioCardia as []

BioCardia, Inc. (NASDAQ:BCDA) CEO Peter Altman purchased 5,000 shares of the companys stock in a transaction that occurred on Thursday, November 18th. The shares were purchased at an average cost of $2.20 per share, for a total transaction of $11,000.00. The transaction was disclosed in a document filed with the SEC, which is available through []

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pu

The stock price of BioCardia Inc (NASDAQ: BCDA) increased by over 4% today. This is why it happened.

SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular dise

SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular an